Using Technology-Assisted Stepped Care Intervention to Improve Adherence in Adolescents With Asthma
Part of paid clinical trials in Cincinnati, Ohio.
- Sponsor
- Children's Hospital Medical Center, Cincinnati
- Study ID
- NCT04365556
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 12 Years - 18 Years
- Healthy Volunteers
- Not accepted
Interventions
- TASC Intervention — BEHAVIORALAll participants receive Step 1 of the intervention. Participants who have adherence below or at 68% will step up to Step 2 or Step 3 after the third or fourth month in the study.
Study Details
To test the preliminary efficacy of the TASC adherence promotion intervention for adolescents with asthma in a feasibility randomized controlled trial compared to treatment as usual control arm.
Key Dates
- Start date
- Nov 19, 2019
- Status verified
- Aug 2025
- Primary completion
- May 24, 2024
- Completion
- Jul 2, 2024
Study Design
- Enrollment
- 72 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: TASC InterventionStep 1 of the intervention includes educational materials related to asthma. Step 2 includes electronic monitoring of adherence and a text messaging intervention personally tailored to the participant. Step 3 includes problem solving telehealth sessions with a trained clinician.
- No Intervention: Treatment as UsualParticipants will not receive any intervention.
Primary Outcome Measure
Percent Change in Inhaler Adherence Via Electronic Monitoring [ Time Frame: 30 days ]
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Cincinnati Children's Medical Hospital | Cincinnati | Ohio | 45229 | - |
Find similar trials in Cincinnati, OH
By condition
By specialty
By research site
Related Studies
- Asthma Inflammation ResearchEARLY_PHASE1 · Enrolling By Invitation · The Cleveland Clinic · Cleveland, Ohio
- Registry of Asthma Characterization and Recruitment 3 (RACR3)Recruiting · National Institute of Allergy and Infectious Diseases (NIAID) · Aurora, Colorado
- A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA)PHASE3 · Recruiting · AstraZeneca · Mobile, Alabama
- A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With AsthmaPHASE3 · Recruiting · GlaxoSmithKline · Birmingham, Alabama